Supportive care plans: Linking patient-reported outcomes to evidence-based supportive care across the cancer continuum E.E. Stevens, J.N. Bottsford-Miller,

Slides:

Advertisements

Similar presentations

Cancer Metabolism Cell Volume 148, Issue 3, (February 2012) DOI: /j.cell Copyright © 2012 Terms and Conditions Terms and Conditions.

Advertisements

CT screening for lung cancer: Is the evidence strong enough? J.K. Field, A. Devaraj, S.W. Duffy, D.R. Baldwin Lung Cancer Volume 91, Pages (January.

Volume 144, Issue 1, Pages (January 2017)

Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade.

Volume 148, Issue 1, Pages (January 2018)

The opportunity for collaborative care provision: the presence of nursing home/hospice collaborations in the U.S. states Susan C. Miller, PhD, Vincent.

Volume 150, Issue 1, Pages (July 2018)

Volume 148, Issue 1, Pages (January 2018)

Are patients willing to travel for better ovarian cancer care?

Volume 148, Issue 1, Pages (January 2018)

L. C. Parsons, S. A. Sullivan, C. Garcia, T. Castellano, V. L

Volume 148, Issue 1, Pages (January 2018)

Volume 146, Issue 3, Pages (September 2017)

A. Melamed, E. J. Diver, A. A. Gockley, E. M. Hinchcliff, L

What Palliative Care-Related Problems Do Patients Experience at HIV Diagnosis? A Systematic Review of the Evidence Victoria M. Simms, MSc, Irene J. Higginson,

Volume 145, Issue 2, Pages (May 2017)

Volume 138, Issue 1, Pages (July 2015)

Vulvar intraepithelial neoplasia: Risk factors for recurrence

Corrigendum to “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer” [Gynecologic Oncology 110: 13–21, 2008] Douglas.

Volume 141, Issue 1, Pages 2-9 (April 2016)

Volume 144, Issue 2, Pages (February 2017)

The efficacy of mTORC1/2 inhibition on ovarian cancer stem cells

Isaac M. Bromberg, MD Journal of Pain and Symptom Management

M. Ulm, D. Lee, A.R. Mabe, M.P. Lowe, S. Kumar, T. Tillmanns

Volume 151, Issue 1, Pages (October 2018)

Wilberto Nieves-Neira, J. Julie Kim, Daniela Matei

Volume 136, Issue 2, Pages (February 2015)

L.M. Bean, F.J. Sulzmaier, D.D. Schlaepfer

Volume 142, Issue 3, Pages (September 2016)

National trends in management of stage IIIC1 and IIIC2 uterine cancer: Chemotherapy and radiotherapy in isolation and sequence J. Chino, J.R. Foote,

Pathologic response at interval debulking surgery following neoadjuvant chemotherapy predicts improved survival in women with ovarian cancer E.N. Prendergast,

K. Bixel, N. Denlinger, L. Marsh, A. Quick, R. Salani

Volume 152, Issue 1, Pages (January 2019)

Volume 143, Issue 2, Pages (November 2016)

Laparoscopic staging for stage I epithelial ovarian cancer: Analysis of the National Cancer Data Base A. Melamed, J.T. Clemmer, N.L. Keating, J.D. Wright,

The origins of multidisciplinary cancer care

Adherence to hematologic hold parameters in dose-dense chemotherapy for ovarian malignancies: A survey of the National Comprehensive Cancer Network (NCCN)

Comparing the health and economic impacts of cervical cancer screening strategies using the Cancer Risk Management Model (CRMM) C. Popadiuk, A.J. Coldman,

I. Mert, A. R. Munkarah, R. K. Hanna, J. Chhina, M. S. Carey, M

Survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum A. Ellis, M.K. Frey, L.M. Koontz, S. Shyne,

Volume 152, Issue 1, Pages (January 2019)

Are ovarian cancer debulking models reliable: Variance and predictability are dependent on institutional optimal debulking rates N.A. Latif, E.M. Ko,

Volume 152, Issue 1, Pages (January 2019)

Volume 147, Issue 1, Pages (October 2017)

Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK , an AKT inhibitor, in patients with recurrent or persistent.

The complex interaction of cancer surgery, complications, and patient-reported outcomes: A single score is not enough K.M. Doll, E.L. Barber, J.T. Bensen,

Volume 142, Issue 2, Pages (August 2016)

Annika Idahl, Andrea Hermansson, Ann Lalos Gynecologic Oncology

Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival: an NRG Oncology/Gynecologic Oncology Group study

Volume 147, Issue 3, Pages (December 2017)

The Number of Pulmonary Metastases: Influence on Practice and Outcome

Volume 152, Issue 1, Pages (January 2019)

Full inguinofemoral lymphadenectomy after positive sentinel inguinofemoral lymph node is associated with greater overall survival in patients with stage.

Volume 152, Issue 1, Pages (January 2019)

Volume 130, Issue 3, Pages (September 2013)

Upregulated Wnt signaling is associated with increased survival of patients with high- grade serous ovarian cancer M. Dandapani, B.L. Seagle, R. Samuelson,

Volume 130, Issue 1, Pages (July 2013)

Volume 152, Issue 1, Pages (January 2019)

Volume 55, Pages S3-S16 (June 1999)

Characteristics of primary peritoneal serous carcinoma in a U. S

European Lung Cancer Conference (ELCC) 2016 Organisation

Volume 152, Issue 1, Pages (January 2019)

Table of Contents Nurse Leader Volume 16, Issue 3, (June 2018)

Volume 147, Issue 3, Pages (December 2017)

Volume 124, Issue 1, Pages (January 2012)

High-risk cancer, unequal care: Disparities in the complete surgical staging of high- grade endometrial cancer in the Southeastern United States J.R.

Should ovarian preservation be considered for women younger than 60 years with endometrial carcinoma? L.M. Bean, K. Taylor, K.M. Anderson, M.A. Davis,

Volume 2, Issue 6, Pages (June 2017)

Volume 115, Issue 1, Pages (October 2009)

Volume 154, Issue 2, Pages (August 2019)

Presentation transcript:

Supportive care plans: Linking patient-reported outcomes to evidence-based supportive care across the cancer continuum E.E. Stevens, J.N. Bottsford-Miller, J. Miller, W.N. Dudley, S. Panzer, C.T. Stricker, J.M. Brant, R.K. Gibb Gynecologic Oncology Volume 141, (June 2016) DOI: 10.1016/j.ygyno.2016.04.351 Copyright © 2015 Terms and Conditions

Fig. 1 Unique-Issue Specific Recommendations (n=292) per Patient (n=44), across All Delivered Care Plans. Gynecologic Oncology 2016 141, DOI: (10.1016/j.ygyno.2016.04.351) Copyright © 2015 Terms and Conditions

Fig. 2 Percentage of Patients (n=44) who Received a Recommendation at Least Once. Gynecologic Oncology 2016 141, DOI: (10.1016/j.ygyno.2016.04.351) Copyright © 2015 Terms and Conditions